Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7986027 | 0.92 | PKM (0.47) | PKMPIK3CDLRRK2FLT3MAP3K1 | |
| SCHEMBL1718320 | 0.91 | PIK3CD (0.45) | PKMPIK3CDLRRK2PDE4DKMT2A | |
| SCHEMBL19434452 | 0.82 | PKM (0.50) | PKMPIK3CDKMT2AKDM4EMEN1 | |
| SCHEMBL7886091 | 0.81 | PKM (0.39) | PKMPIK3CDLRRK2FLT3MAP3K1 | |
| SCHEMBL7886096 | 0.81 | PKM (0.39) | PKMPIK3CDLRRK2FLT3MAP3K1 | |
| SCHEMBL1718493 | 0.80 | PKM (0.51) | PKMMAP3K12KMT2AKDM4EMEN1 | |
| SCHEMBL1665273 | 0.80 | PKM (0.55) | PKMMAP3K12KMT2AKDM4EMEN1 | |
| SCHEMBL6342254 | 0.79 | PKM (0.44) | PKMPIK3CDLRRK2KMT2AKDM4E | |
| SCHEMBL2076461 | 0.78 | PKM (0.57) | PKMMAP3K12KMT2AKDM4EMEN1 | |
| SCHEMBL15417567 | 0.78 | PKM (0.39) | PKMLRRK2KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300478-B1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-9102679-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102679-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140350025-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| EP-2414363-B1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-8623901-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623879-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623879-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623901-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| WO-2010112437-A1 | 1-HETEROCYCLYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| WO-2009121919-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | PKM 333/4885PIK3CD 1321/4885LRRK2 2358/4885 |
| US-20140350025-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CHRM1, ATP6V1B2, CNR1 | PKM 255/4885PIK3CD 2844/4885LRRK2 1371/4885 |
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CHRM1, CHRM2, CHRM5 | PKM 265/4885PIK3CD 3377/4885LRRK2 1355/4885 |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | PKM 857/4885PIK3CD 1077/4885LRRK2 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.